工程化T细胞分泌的TIM-3-Fc诱饵受体改善B细胞急性淋巴细胞白血病中的CD19 CAR T细胞治疗
本研究分析了B-ALL骨髓微环境中免疫检查点受体及其配体的表达,发现T细胞TIM-3及白血病母细胞和间充质基质细胞的galectin-9随疾病进展显著上调,且与CAR19 T细胞临床结局负相关。galectin-9损害CAR19 T细胞稳态和细胞毒性,而TIM-3-Fc诱饵受体可提高B-ALL异种移植模型中CAR19 T细胞的抗白血病疗效和持久性。
要点
- B-ALL进展中T细胞TIM-3及母细胞和MSC的galectin-9表达显著上调。
- galectin-9损害CAR19 T细胞稳态和细胞毒性。
- TIM-3-Fc诱饵受体增强B-ALL异种移植模型中CAR19 T细胞疗效和持久性。
核心结论
- TIM-3-Fc诱饵受体装甲的CAR19 T细胞为复发或难治性B-ALL患者提供了一种有前景的治疗策略。
研究设计与样本
- 研究比较了诊断和复发时B-ALL骨髓样本中白血病母细胞、T细胞和间充质基质细胞的免疫检查点受体及其配体表达与年龄匹配健康骨髓对照。
- 在B-ALL异种移植模型中测试了TIM-3-Fc诱饵受体的两种递送方式:原代T细胞与CAR19 T细胞共输注,或双顺反子all-in-one CAR19-TIM-3-Fc构建体。
- 采用光谱流式细胞术检测转导和旁观者效应及记忆T细胞的体内扩增。
主要发现
- T细胞TIM-3及母细胞和MSC的galectin-9表达在整个疾病进展中显著上调。
- B-ALL母细胞galectin-9表达和CAR19 T细胞TIM-3表达与临床结局负相关。
- galectin-9损害CAR19 T细胞稳态和细胞毒性。
- TIM-3-Fc诱饵受体(共输注或双顺反子构建体)改善B-ALL异种移植模型中CAR19 T细胞的抗白血病疗效和持久性。
- CAR19-TIM-3-Fc T细胞治疗促进转导和旁观者效应及记忆T细胞的体内扩增。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) remains a challenging disease with dismal prognosis. Despite the revolutionary impact of CD19-directed chimeric antigen receptor (CAR19) T-cell therapy, >50% of patients relapse within a year. Both leukemia cell-intrinsic factors favoring immune escape and poor CAR T-cell persistence contribute to clinical failure. Moreover, the expression of immune checkpoint receptors (ICRs) and their ligands within the bone marrow (BM) microenvironment may contribute to leukemia progression and therapy resistance. Here, we characterized the expression of ICRs and their ligands in leukemic blasts, T cells, and mesenchymal stromal cells (MSCs) from B-ALL BM samples at diagnosis and relapse, comparing them with age-matched healthy BM controls. Our findings reveal a significantly upregulated expression of TIM-3 in T cells and its ligand, galectin-9, in both blasts and MSCs throughout disease progression. The expression of galectin-9 in B-ALL blasts and TIM-3 in CAR19 T cells negatively correlates with clinical outcome. Furthermore, we demonstrate that galectin-9 impairs CAR19 T-cell homeostasis and cytotoxicity. Notably, an engineered TIM-3-Fc decoy receptor, delivered either by primary T cells coadministered with CAR19 T cells or via a bicistronic all-in-one CAR19-TIM-3-Fc construct, improved the antileukemia efficacy and persistence of CAR19 T cells in B-ALL xenograft models. Mechanistically, CAR19-TIM-3-Fc T-cell treatment promotes the in vivo expansion of transduced and bystander effector and memory T cells, as determined by spectral flow cytometry. Collectively, these TIM-3-Fc decoy-armored CAR19 T cells offer a promising therapeutic strategy for patients with R/R B-ALL.
引用
- Falgàs A, Lázaro-Gorines R, Zanetti SR, et al. A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia. Blood. 2025. PMID: 40090006. doi:10.1182/blood.2024025440
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。